| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions |
Primary endpoint(s) modified |
| 2026-06-06 | NCT04074096 Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma… |
date change Primary completion pushed: 2026-03-27 -> 2026-05-07 |
| 2026-06-06 | NCT04074096 Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma… |
date change Completion pushed: 2026-03-27 -> 2027-03-27 |
| 2026-06-06 | NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… |
date change Primary completion moved earlier: 2029-02-02 -> 2028-04-23 |
| 2026-06-06 | NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… |
date change Completion moved earlier: 2030-08-06 -> 2029-10-25 |
| 2026-05-15 | NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… |
Trial sites expanded: 18 -> 40 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05615818 | Personalized Medicine for Advanced Biliary Cancer Patients | Biliary Tract Neoplasms | Recruiting |
| NCT04657991 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab)… | Melanoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT04322383 | Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and… | Hairy Cell Leukemia | Recruiting |
| NCT04324112 | Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | Hairy Cell Leukemia | Recruiting |
| NCT05286788 | MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Adamantinous Craniopharyngioma | Recruiting |
| NCT05026983 | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous… | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recruiting |
| NCT04598009 | Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | Melanoma Stage III | Recruiting |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced… | Advanced Malignant Solid Neoplasm | Recruiting |
| NCT05170334 | Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | Active, Not Recruiting |
| NCT04061980 | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With… | BRAF NP_004324.2:p.V600M | Active, Not Recruiting |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating… | Stage III Breast Cancer | Active, Not Recruiting |
| NCT05195632 | Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT04439344 | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic… | Advanced Lymphoma | Active, Not Recruiting |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | Exocrine Pancreas Carcinoma | Active, Not Recruiting |
| NCT05564403 | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in… | Advanced Biliary Tract Carcinoma | Active, Not Recruiting |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… | Advanced Lymphoma | Active, Not Recruiting |
| NCT04074096 | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma… | Malignant Melanoma | Active, Not Recruiting |
| NCT03839342 | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E… | Solid Tumor | Active, Not Recruiting |
| NCT02910700 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating… | Metastatic Malignant Neoplasm in the Brain | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Metastatic Uveal Melanoma | Recruiting |
| Phase 1 | |||
| NCT04903119 | Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma | Metastatic Melanoma | Recruiting |
| NCT05355701 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… | Melanoma | Recruiting |
| Early Phase 1 | |||
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | Melanoma (Skin) | Active, Not Recruiting |